The pregnancy group had longer DFS in HER2 positive BC patients, although this difference was not statistically significant (22, 38) [HR = 0.90, 95% CI (0.49, 1.66), P = 0.737] (Figure C.16). This evidence concerns the gene ERBB2 and breast cancer.